265 related articles for article (PubMed ID: 10845730)
1. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.
Betts T; Waegemans T; Crawford P
Seizure; 2000 Mar; 9(2):80-7. PubMed ID: 10845730
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of levetiracetam: a review of three pivotal clinical trials.
Privitera M
Epilepsia; 2001; 42 Suppl 4():31-5. PubMed ID: 11564123
[TBL] [Abstract][Full Text] [Related]
3. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
Abou-Khalil B; Hemdal P; Privitera MD
Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group.
Ben-Menachem E; Falter U
Epilepsia; 2000 Oct; 41(10):1276-83. PubMed ID: 11051122
[TBL] [Abstract][Full Text] [Related]
5. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures.
Wu XY; Hong Z; Wu X; Wu LW; Wang XF; Zhou D; Zhao ZX; Lv CZ
Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study.
Beran RG; Berkovic SF; Black AB; Danta G; Hiersemenzel R; Schapel GJ; Vajda FJ
Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083
[TBL] [Abstract][Full Text] [Related]
7. Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies.
Rosenfeld WE; Benbadis S; Edrich P; Tassinari CA; Hirsch E
Epilepsy Res; 2009 Jul; 85(1):72-80. PubMed ID: 19327967
[TBL] [Abstract][Full Text] [Related]
8. Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy.
Boon P; Chauvel P; Pohlmann-Eden B; Otoul C; Wroe S
Epilepsy Res; 2002 Jan; 48(1-2):77-89. PubMed ID: 11823112
[TBL] [Abstract][Full Text] [Related]
9. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures.
Piña-Garza JE; Nordli DR; Rating D; Yang H; Schiemann-Delgado J; Duncan B;
Epilepsia; 2009 May; 50(5):1141-9. PubMed ID: 19243423
[TBL] [Abstract][Full Text] [Related]
10. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study.
Callenbach PM; Arts WF; ten Houten R; Augustijn P; Gunning WB; Peeters EA; Weber AM; Stroink H; Geerts Y; Geerts AT; Brouwer OF
Eur J Paediatr Neurol; 2008 Jul; 12(4):321-7. PubMed ID: 17950011
[TBL] [Abstract][Full Text] [Related]
11. Levetiracetam in patients with refractory epilepsy: results of the SKATE trial in Austria, Germany and Switzerland.
Steinhoff BJ; Trinka E; Wieser HG;
Seizure; 2005 Oct; 14(7):490-6. PubMed ID: 16169256
[TBL] [Abstract][Full Text] [Related]
12. Assessment of a dose-response relationship of levetiracetam.
Meencke HJ; Buyle S
Eur J Neurol; 2006 Sep; 13(9):942-6. PubMed ID: 16930358
[TBL] [Abstract][Full Text] [Related]
13. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.
Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM;
Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886
[TBL] [Abstract][Full Text] [Related]
14. Effect of levetiracetam in patients with epilepsy and interictal epileptiform discharges.
Stodieck S; Steinhoff BJ; Kolmsee S; van Rijckevorsel K
Seizure; 2001 Dec; 10(8):583-7. PubMed ID: 11792161
[TBL] [Abstract][Full Text] [Related]
15. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
[TBL] [Abstract][Full Text] [Related]
16. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group.
Shorvon SD; Löwenthal A; Janz D; Bielen E; Loiseau P
Epilepsia; 2000 Sep; 41(9):1179-86. PubMed ID: 10999557
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy.
Grant R; Shorvon SD
Epilepsy Res; 2000 Dec; 42(2-3):89-95. PubMed ID: 11074181
[TBL] [Abstract][Full Text] [Related]
18. Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial.
Genton P; Sadzot B; Fejerman N; Peltola J; Despland PA; Steinhoff B; Rektor I; Wroe S; Maubrey MC; Vandervelden C; van Hammée G; Schlit AF; van Paesschen W
Acta Neurol Scand; 2006 Jun; 113(6):387-94. PubMed ID: 16674605
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy.
Grosso S; Franzoni E; Coppola G; Iannetti P; Verrotti A; Cordelli DM; Marchiani V; Pascotto A; Spalice A; Acampora B; Morgese G; Balestri P
Seizure; 2005 Jun; 14(4):248-53. PubMed ID: 15911359
[TBL] [Abstract][Full Text] [Related]
20. Levetiracetam extended release conversion to monotherapy for the treatment of patients with partial-onset seizures: a double-blind, randomised, multicentre, historical control study.
Chung S; Ceja H; Gawłowicz J; Avakyan G; McShea C; Schiemann J; Lu S
Epilepsy Res; 2012 Aug; 101(1-2):92-102. PubMed ID: 22516508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
